Citi Sticks to Its Buy Rating for Acumen Pharmaceuticals (ABOS)
Citi analyst Geoff Meacham maintains a Buy rating for Acumen Pharmaceuticals with a $4.00 price target. Shares closed at $1.95. Meacham, a 4-star analyst, has a 5.7% average return and 56.39% success rate, focusing on Healthcare stocks. Acumen has a Strong Buy consensus with a $5.67 price target.
In a report released yesterday, Geoff Meacham from Citi maintained a Buy rating on Acumen Pharmaceuticals, with a price target of $4.00. The company’s shares closed yesterday at $1.95.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Meacham is a 4-star analyst with an average return of 5.7% and a 56.39% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Vertex Pharmaceuticals, and BioNTech SE.
Acumen Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $5.67.
